Legend’s subsidiary is licensing LB2102 and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 to Novartis for $100 million upfront with the potential to receive up to $1.1 billion in milestone payments.
Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?
J&J’s Rybrevant-based combo could take share from AstraZeneca’s Tagrisso in EGFR-mutant lung cancer, initial data suggest. Just how much will be the subject of debate.
Merck turns to testimonials to encourage lung-cancer screenings
Celgene reportedly in talks to buy Juno; Novartis’ Kymriah receives fast-track reviews in U.S. and Europe; BI’s Gilotrif gets expanded approval in lung cancer
Five things for pharma marketers to know: Friday, February 24, 2017